The FDA may soon clear a path for promising drug treatments for patients showing signs of Alzheimer’s disease in order to foster development and commercial availability and fill the void for this as yet untreatable disease, according to an article in the March issue of the New England Journal of Medicine.

The FDA has approved an injectable diagnostic imaging agent to help physicians pinpoint lymph nodes that drain potentially invasive tumors to better manage patients with metastatic breast cancer and melanoma.

IBA Molecular has opened production and distribution of zirconium-89 for preclinical and investigational use with PET for distribution five days a week.

MRI soon after a mild concussion, or mild traumatic brain injury (mTBI), can detect small lesions and may help refine treatment for people with mTBI, according to research that will be presented at the American Academy of Neurology annual meeting in San Diego, March 16 to 23.

Lantheus Medical Imaging has appointed Cesare Orlandi, MD, to serve as its next chief medical officer (CMO).

Dexmedetomidine (DEX), approved in 2008 by the FDA for use in sedation, may offer a safe, effective and efficient alternative to sedatives currently used in pediatric nuclear medicine imaging, according to a study published in the February edition of Radiology. DEX presents itself as a safer method of sedation during a time of growing demand for pediatric PET oncologic and epileptic scanning.

A diffusion tensor imaging (DTI) study has shown that multiple sclerosis (MS) patients with cognitive problems have more damage to areas of the brain involved with cognitive processes compared with MS patients who don’t suffer from cognitive problems, according to the results of the study published online March 6 in Neurology.

I have been talking to various audiences over the past five years about the potential of molecular imaging in the care of our patients.